Compound News and Research

RSS

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release tablets.

20 Jul 2010

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

Pfizer Inc. today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

20 Jul 2010

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

17 Jul 2010

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

As a national research university, Florida Institute of Technology not only involves its students in research, but also seeks to license and patent its many innovations. An example of recently licensed university technology is a chemical compound that facilitates the work of neuroscientists in the laboratory.Associate Professor Nasri Nesnas was familiar as a chemist with the chemical compound CDNI-Glu, a commonly used laboratory research tool. Most often, neuroscientists use it to study the brain's neural networks by improving the localization of synaptic stimulation

17 Jul 2010

Resveratrol concentration impacts cancer risk mitigation: Study

Agricultural Research Service (ARS) chemist Thomas Wang, who specializes in cancer prevention research, has reported evidence that for some dietary compounds, length of exposure over time may be key to whether or not ingestion leads to a beneficial, or detrimental, effect.Scientists do not know exactly why one person develops cancer and another does not. But they do know that certain nutrients might increase or decrease cancer risk. There are "layers" of factors involved in the development of cancer, and Wang is studying the layers involving peoples' diet complexity and gene expression.

17 Jul 2010

Research findings may help identify human TOR kinase inhibitors

A parasite estimated to afflict as many as 12 million people worldwide relies on a family of genes that should make it vulnerable to compounds developed to treat cancer and other disorders, researchers at Washington University School of Medicine in St. Louis have found.

17 Jul 2010

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

ALOKA CO., LTD., announced on July 16 the ProSound F75, a high-end color diagnostic ultrasound system of the new "F" series at its private exhibition, "Aloka Fair 2010." This new flagship of multi-purpose systems, providing unprecedented performance in a variety of clinical applications, is comfortable and easy to use.

16 Jul 2010

Scientists discover gene mutation responsible for CDG

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, has discovered the gene mutation responsible for a condition in which eye and brain development is severely disrupted in affected infants.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

15 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

No harmful levels of benzene, other compounds emitted from natural gas sites: BSEEC study

The Barnett Shale Energy Education Council today released the results of its air quality testing project which showed there are no harmful levels of benzene and other compounds being emitted from natural gas sites tested in Fort Worth and Arlington City Council District 2.

15 Jul 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

A new study being published in the journal Urology shows that Proantinox, a proprietary cranberry-based blend used successfully in hospitals and long-term care facilities as UTI-Stat, and now available directly to consumers as new Cystex Liquid Cranberry Complex with Proantinox, is safe and effective in significantly reducing the incidence of UTIs in women at risk for recurring infections.

15 Jul 2010

Evotec to acquire DeveloGen

Evotec AG today announced the signing of a definitive agreement to acquire DeveloGen, a biopharmaceutical company engaged in the discovery of novel therapeutic approaches for the treatment of metabolic and endocrine disorders, for up to €14m in shares plus performance-related deferred payments (earn-out).

15 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

Insight into inner functional mechanisms of new bacterial infection target

In any battle, sizing up one's opponent is a critical first step. For researchers fighting a bacterial infection, that means assessing every nook and cranny of the malicious microorganism and identifying which ones to attack.

14 Jul 2010

Compound News and Research

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Pfizer suspends chronic low back pain, diabetic peripheral neuropathy studies in tanezumab clinical program

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

Resveratrol concentration impacts cancer risk mitigation: Study

Research findings may help identify human TOR kinase inhibitors

ALOKA announces new ProSound F75 high-end color diagnostic ultrasound system

Scientists discover gene mutation responsible for CDG

Columbia scientists discover new way to alleviate chronic pain

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

Activities of TAT fully consolidated into Geron

No harmful levels of benzene, other compounds emitted from natural gas sites: BSEEC study

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

New Cystex Liquid Cranberry Complex with Proantinox reduces incidence of UTIs in women: Study

Evotec to acquire DeveloGen

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

Insight into inner functional mechanisms of new bacterial infection target

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News